DE60318567T2 - Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems - Google Patents

Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems Download PDF

Info

Publication number
DE60318567T2
DE60318567T2 DE60318567T DE60318567T DE60318567T2 DE 60318567 T2 DE60318567 T2 DE 60318567T2 DE 60318567 T DE60318567 T DE 60318567T DE 60318567 T DE60318567 T DE 60318567T DE 60318567 T2 DE60318567 T2 DE 60318567T2
Authority
DE
Germany
Prior art keywords
alkyl
benzothiazol
pyrimidin
methyl
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318567T
Other languages
German (de)
English (en)
Other versions
DE60318567D1 (de
Inventor
P. Domaine de la Prasle GAILLARD
Jean-Pierre Gotteland
Pierre-Alain Vitte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Serono Laboratories UK Ltd
Original Assignee
Laboratoires Serono SA
Serono Laboratories UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA, Serono Laboratories UK Ltd filed Critical Laboratoires Serono SA
Publication of DE60318567D1 publication Critical patent/DE60318567D1/de
Application granted granted Critical
Publication of DE60318567T2 publication Critical patent/DE60318567T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60318567T 2002-04-25 2003-04-25 Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems Expired - Lifetime DE60318567T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02100417 2002-04-25
EP02100417 2002-04-25
PCT/EP2003/004323 WO2003091249A1 (en) 2002-04-25 2003-04-25 Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders

Publications (2)

Publication Number Publication Date
DE60318567D1 DE60318567D1 (de) 2008-02-21
DE60318567T2 true DE60318567T2 (de) 2009-02-19

Family

ID=29265991

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60318567T Expired - Lifetime DE60318567T2 (de) 2002-04-25 2003-04-25 Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems

Country Status (22)

Country Link
US (1) US7314878B2 (enExample)
EP (1) EP1501828B1 (enExample)
JP (1) JP4523289B2 (enExample)
KR (1) KR100948469B1 (enExample)
CN (1) CN1310911C (enExample)
AT (1) ATE383356T1 (enExample)
AU (1) AU2003233067B2 (enExample)
BR (1) BRPI0309594A8 (enExample)
CA (1) CA2481763C (enExample)
CY (1) CY1107204T1 (enExample)
DE (1) DE60318567T2 (enExample)
DK (1) DK1501828T3 (enExample)
EA (1) EA009682B1 (enExample)
ES (1) ES2297165T3 (enExample)
IL (2) IL164796A0 (enExample)
MX (1) MXPA04010474A (enExample)
PT (1) PT1501828E (enExample)
RS (1) RS51407B (enExample)
SI (1) SI1501828T1 (enExample)
UA (1) UA78035C2 (enExample)
WO (1) WO2003091249A1 (enExample)
ZA (1) ZA200408023B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60318567T2 (de) 2002-04-25 2009-02-19 Laboratoires Serono S.A., Coinsins Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems
HRP20070527T3 (en) * 2003-09-12 2007-12-31 Laboratoires Serono Sa Benzothiazole derivatives for the treatment of diabetes
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
JP5144271B2 (ja) * 2004-11-17 2013-02-13 アレス トレーディング ソシエテ アノニム ベンゾチアゾ−ル製剤、及びそれらの使用
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
BRPI0613042A2 (pt) * 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
WO2008125518A2 (en) * 2007-04-17 2008-10-23 Merck Serono S.A. Process for the preparation of piperazine benzothiazoles
KR101368079B1 (ko) * 2008-05-16 2014-03-14 에프. 호프만-라 로슈 아게 Ｊｎｋ 의 억제제
CA2799328C (en) * 2010-06-04 2018-02-20 Humberto Bartolome Arzeno 2 -amino- pyrimidine derivatives useful as inhibitors of jnk
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4153574B2 (ja) * 1997-09-10 2008-09-24 トーアエイヨー株式会社 新規なピペリジン誘導体、その製造法およびそれを含有する循環器官用剤
EP1110957A1 (en) * 1999-12-24 2001-06-27 Applied Research Systems ARS Holding N.V. Benzazole derivatives and their use as JNK modulators
EP1193256A1 (en) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmaceutically active benzsulfonamide derivatives as inhibitors of JNK proteins
DE60318567T2 (de) 2002-04-25 2009-02-19 Laboratoires Serono S.A., Coinsins Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns-systems

Also Published As

Publication number Publication date
IL164796A (en) 2013-02-28
EP1501828B1 (en) 2008-01-09
US20050261304A1 (en) 2005-11-24
ZA200408023B (en) 2005-11-30
ES2297165T3 (es) 2008-05-01
SI1501828T1 (sl) 2008-04-30
DK1501828T3 (da) 2008-03-10
AU2003233067A1 (en) 2003-11-10
AU2003233067B2 (en) 2009-01-08
DE60318567D1 (de) 2008-02-21
CA2481763A1 (en) 2003-11-06
BRPI0309594A2 (pt) 2016-11-16
EA009682B1 (ru) 2008-02-28
RS92804A (sr) 2006-12-15
EP1501828A1 (en) 2005-02-02
CA2481763C (en) 2011-06-14
PT1501828E (pt) 2008-02-11
MXPA04010474A (es) 2004-12-13
KR100948469B1 (ko) 2010-03-17
EA200401423A1 (ru) 2005-04-28
WO2003091249A1 (en) 2003-11-06
KR20040104572A (ko) 2004-12-10
UA78035C2 (en) 2007-02-15
RS51407B (sr) 2011-02-28
CN1310911C (zh) 2007-04-18
BRPI0309594A8 (pt) 2017-04-11
ATE383356T1 (de) 2008-01-15
CY1107204T1 (el) 2012-11-21
JP2006504631A (ja) 2006-02-09
CN1662528A (zh) 2005-08-31
IL164796A0 (en) 2005-12-18
JP4523289B2 (ja) 2010-08-11
US7314878B2 (en) 2008-01-01
HK1075664A1 (en) 2005-12-23

Similar Documents

Publication Publication Date Title
DE69724108T2 (de) Isochinolinderivate und arzneimittel
DE60316468T2 (de) Pyrimidine verbindungen
DE69321087T2 (de) Alpha-aminoketon Derivate
DE60006580T2 (de) Benzazolderivate und ihre verwendung als jnk modulatoren
DE10148618B4 (de) Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE60103909T2 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
DE60129154T2 (de) Neuartige verbindungen
CN106061947A (zh) 环己基砜RORγ调节剂
WO1999054304A1 (de) Heterozyklische substituierte amide, deren herstellung und anwendung
KR100948469B1 (ko) 뇌경색 질환 또는 ｃｎｓ 질환의 치료를 위한 약물로서의피페라진 벤조티아졸
DE69815137T2 (de) Epoxybernsteinsäureamid-derivate
DD290884A5 (de) Verfahren zur herstellung von pyridyl- und pyrimidylderivaten
DE60104130T2 (de) 1-(alkyl), 1-[(heteroaryl)alkyl] und 1-[(aryl)alkyl]-7-pyridinyl-imidazo[1,2-a]pyrimidin-5(1h)-onderivate
DE602005005211T2 (de) Neue azaindol-thiazolinone als krebsmittel
EP0303951A2 (de) 2-Pyrimidinyl-1-piperazin-Derivate zur Behandlung von Alkoholismus
DE60106974T2 (de) Aminotriazolopyridinderivate als adenosinrezeptorliganden
DE3854981T2 (de) 1-Pyrrolidinacetamid-Derivate und ihre Verwendung
US9095575B2 (en) Derivatives of 1-(substituted sulfonyl)-2-aminoimidazoline as antitumor and antiproliferative agents
DE68912263T2 (de) 4-Methyl-5[2-(4-phenyl-1-piperazinyl)-ethyl]-Thiazolderivate, ihre Herstellung und Zusammenstellungen, die sie enthalten.
DE69609382T2 (de) Amidin-Derivate und Blutplättchen-Aggregationsinhibitoren, die sie enthalten
DE69629931T2 (de) 1-(hetero)aryl-4-(kondensiertes thiazol-2-ylalkyl)-piperazin derivate, deren herstellung und deren verwendung in der behandlung von 5-ht1a-rezeptor vermittelten krankheiten
DE10148617A1 (de) Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE102005020104A1 (de) Neue Thiazolidinone ohne basischen Stickstoff, deren Herstellung und Verwendung als Arzneimittel
WO2025122501A1 (en) Benzothiophene-3-yl- and benzoselenophene-3-yl (biclyclic heteroaryl) malemides as gsk-3 inhibitors
DE60003214T2 (de) Benz[f]indole zur verwendung in der behandlung von 5ht-rezeptor relatierten störungen

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: GAILLARD, P. DOMAINE DE LA PRASLE, ST. JULIEN-, FR

Inventor name: GOTTELAND, JEAN-PIERRE, BEAUMONT, FR

Inventor name: VITTE, PIERRE-ALAIN, CRANVES-SALES, FR

8364 No opposition during term of opposition